Pro Share Advisors LLC Ligand Pharmaceuticals Inc Transaction History

Pro Share Advisors LLC

  • $39.7 Billion
  • Q3 2024

A detailed history of Pro Share Advisors LLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Pro Share Advisors LLC holds 4,654 shares of LGND stock, worth $519,200. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,654
Previous 3,703 25.68%
Holding current value
$519,200
Previous $312,000 49.36%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$82.7 - $110.11 $78,647 - $104,714
951 Added 25.68%
4,654 $466,000
Q2 2024

Aug 13, 2024
SELL
$68.53 - $87.91 $63,321 - $81,228
-924 Reduced 19.97%
3,703 $312,000
Q1 2024

May 08, 2024
BUY
$68.64 - $89.2 $24,916 - $32,379
363 Added 8.51%
4,627 $338,000
Q4 2023

Feb 14, 2024
BUY
$49.57 - $72.63 $29,692 - $43,505
599 Added 16.34%
4,264 $304,000
Q3 2023

Nov 13, 2023
SELL
$58.86 - $72.67 $2,884 - $3,560
-49 Reduced 1.32%
3,665 $219,000
Q2 2023

Aug 10, 2023
BUY
$69.53 - $79.33 $21,693 - $24,750
312 Added 9.17%
3,714 $267,000
Q1 2023

May 11, 2023
SELL
$65.67 - $77.08 $26,859 - $31,525
-409 Reduced 10.73%
3,402 $250,000
Q4 2022

Feb 02, 2023
BUY
$61.72 - $96.74 $17,528 - $27,474
284 Added 8.05%
3,811 $254,000
Q3 2022

Nov 04, 2022
BUY
$0.01 - $107.56 $0 - $3,226
30 Added 0.86%
3,527 $304,000
Q2 2022

Aug 01, 2022
SELL
$74.52 - $117.06 $123,479 - $193,968
-1,657 Reduced 32.15%
3,497 $311,000
Q1 2022

May 10, 2022
SELL
$94.99 - $151.56 $96,794 - $154,439
-1,019 Reduced 16.51%
5,154 $580,000
Q4 2021

Feb 08, 2022
BUY
$127.69 - $165.85 $31,284 - $40,633
245 Added 4.13%
6,173 $953,000
Q3 2021

Nov 12, 2021
SELL
$102.33 - $144.73 $228,502 - $323,182
-2,233 Reduced 27.36%
5,928 $826,000
Q2 2021

Aug 13, 2021
BUY
$113.03 - $155.64 $82,624 - $113,772
731 Added 9.84%
8,161 $1.07 Million
Q1 2021

May 14, 2021
BUY
$99.52 - $215.83 $49,560 - $107,483
498 Added 7.18%
7,430 $1.13 Million
Q4 2020

Feb 09, 2021
BUY
$80.55 - $106.05 $119,777 - $157,696
1,487 Added 27.31%
6,932 $689,000
Q3 2020

Nov 13, 2020
SELL
$89.56 - $126.72 $12,448 - $17,614
-139 Reduced 2.49%
5,445 $519,000
Q2 2020

Aug 03, 2020
BUY
$68.28 - $123.65 $104,127 - $188,566
1,525 Added 37.57%
5,584 $625,000
Q1 2020

May 15, 2020
SELL
$63.37 - $107.88 $224,836 - $382,758
-3,548 Reduced 46.64%
4,059 $295,000
Q4 2019

Feb 12, 2020
SELL
$96.94 - $113.59 $104,986 - $123,017
-1,083 Reduced 12.46%
7,607 $793,000
Q3 2019

Nov 12, 2019
SELL
$86.25 - $120.16 $109,882 - $153,083
-1,274 Reduced 12.79%
8,690 $865,000
Q2 2019

Aug 13, 2019
SELL
$107.38 - $129.34 $189,418 - $228,155
-1,764 Reduced 15.04%
9,964 $1.14 Million
Q1 2019

May 15, 2019
BUY
$105.93 - $142.47 $30,295 - $40,746
286 Added 2.5%
11,728 $1.47 Million
Q4 2018

Feb 14, 2019
SELL
$128.36 - $272.13 $128,745 - $272,946
-1,003 Reduced 8.06%
11,442 $1.55 Million
Q3 2018

Nov 14, 2018
SELL
$211.18 - $274.49 $98,621 - $128,186
-467 Reduced 3.62%
12,445 $3.42 Million
Q2 2018

Aug 13, 2018
SELL
$150.77 - $207.98 $99,357 - $137,058
-659 Reduced 4.86%
12,912 $2.68 Million
Q1 2018

May 14, 2018
SELL
$138.63 - $182.62 $284,746 - $375,101
-2,054 Reduced 13.15%
13,571 $2.24 Million
Q4 2017

Feb 14, 2018
BUY
$128.36 - $147.04 $186,763 - $213,943
1,455 Added 10.27%
15,625 $2.14 Million
Q3 2017

Nov 13, 2017
BUY
$120.91 - $137.94 $108,698 - $124,008
899 Added 6.77%
14,170 $1.93 Million
Q2 2017

Aug 11, 2017
BUY
N/A
13,271
13,271 $1.61 Million

Others Institutions Holding LGND

# of Institutions
257
Shares Held
18.2M
Call Options Held
26.8K
Put Options Held
9.3K
View Full List

About LIGAND PHARMACEUTICALS INC

LGND Quotes by TradingView
  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.88B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email